We included studies that met the following criteria: (1) involved patients with cytological or histologically confirmed HER2-positive breast cancer; (2) compared two or more treatments in second-line setting for trastuzumab-treated HER2-positive breast cancer; (3) reported endpoints: progression free survival (PFS), and (or) overall survival (OS); (4) were designed as RCTs. Articles or abstracts that did not meet any above criteria were excluded.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.